Focused On-demand Library for Cilia- and flagella-associated protein 58

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q5T655

UPID:
CFA58_HUMAN

ALTERNATIVE NAMES:
Coiled-coil domain-containing protein 147

ALTERNATIVE UPACC:
Q5T655; D3DRA6; Q8NA27

BACKGROUND:
The essential function of Cilia- and flagella-associated protein 58, known alternatively as Coiled-coil domain-containing protein 147, is underscored by its involvement in the assembly and organization of the sperm flagellar axoneme. It is instrumental in primary cilium elongation and sperm flagellar midpiece development, acting through the Notch signaling pathway.

THERAPEUTIC SIGNIFICANCE:
Given its association with Spermatogenic failure 49, characterized by reduced sperm motility and morphological abnormalities, the study of Cilia- and flagella-associated protein 58 holds significant therapeutic promise. Exploring its function and pathway could lead to innovative treatments for infertility disorders stemming from flagellar anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 76 of 8789